TTY Biopharm Co Ltd (4105) - Total Liabilities

Latest as of December 2025: NT$3.30 Billion TWD ≈ $103.86 Million USD

Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has total liabilities worth NT$3.30 Billion TWD (≈ $103.86 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TTY Biopharm Co Ltd cash conversion from operations to assess how effectively this company generates cash.

TTY Biopharm Co Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how TTY Biopharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 4105 financial resilience to evaluate the company's liquid asset resilience ratio.

TTY Biopharm Co Ltd Competitors by Total Liabilities

The table below lists competitors of TTY Biopharm Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Queen's Road Capital Investment Ltd. TO:QRC	Canada	CA$40.17 Million
Vital Farms Inc NASDAQ:VITL	USA	$167.48 Million
Beijing Quanshi World Online Net SHE:002995	China	CN¥288.36 Million
Sichuan Meifeng Chemical Industry Co Ltd SHE:000731	China	CN¥797.08 Million
Anhui Wantong Technology Co Ltd SHE:002331	China	CN¥1.29 Billion
Opthea Ltd AU:OPT	Australia	AU$256.70 Million
Audax Renovables S.A. MC:ADX	Spain	€1.06 Billion
DXN HOLDINGS BHD. KLSE:5318	Malaysia	RM680.96 Million

Liability Composition Analysis (2017–2025)

This chart breaks down TTY Biopharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of TTY Biopharm Co Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how TTY Biopharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for TTY Biopharm Co Ltd (2017–2025)

The table below shows the annual total liabilities of TTY Biopharm Co Ltd from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$3.30 Billion ≈ $103.86 Million	-1.64%
2024-12-31	NT$3.35 Billion ≈ $105.60 Million	-0.50%
2023-12-31	NT$3.37 Billion ≈ $106.13 Million	+0.04%
2022-12-31	NT$3.37 Billion ≈ $106.09 Million	-4.59%
2021-12-31	NT$3.53 Billion ≈ $111.19 Million	+7.51%
2020-12-31	NT$3.28 Billion ≈ $103.42 Million	-2.98%
2019-12-31	NT$3.38 Billion ≈ $106.60 Million	+27.13%
2018-12-31	NT$2.66 Billion ≈ $83.85 Million	-21.61%
2017-12-31	NT$3.40 Billion ≈ $106.97 Million	--

About TTY Biopharm Co Ltd

TWO:4105 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$581.27 Million

NT$18.45 Billion TWD

Market Cap Rank

#11785 Global

#400 in Taiwan

Share Price

NT$74.20

Change (1 day)

+0.41%

52-Week Range

NT$72.10 - NT$86.30

All Time High

NT$97.91